文献詳細
特集 進行性腎癌に対する分子標的治療薬・薬剤選択ガイド
文献概要
要旨 分子標的薬の導入により進行性腎細胞癌,特に有転移症例の治療は大きく変わった。ただし,新たな薬剤については,その効果を最大限引き出しているとはいいがたい面がある。本項では,併用療法と逐次療法について,その概要を述べる。
参考文献
1)Gollob JA:Phase Ⅱ trial of sorafenib plus interferon alfa-2b as firstor second-line therapy in patients with metastatic renal cell cancer. J Clin Oncol 25:3288, 2007
2)Ryan CW:Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma:a phase Ⅱ study of the southwest oncology group. J Clin Oncol 25:3296, 2007
3)Jonasch E:Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma. Clinical and Biomarker Analysis Cancer 116:57, 2010
4)Bracarda S:Randomized prospective phase Ⅱ trial of two schedules of sorafenib daily and interferon-a2a in metastatic renal cell carcinoma(RAPSODY)GOIRC study 0681. ASCO GU 2008, abstract 357
5)Niwakawa M:Phase Ⅰ trial of sorafenib in combination with interferon-alpha in Japanese patients with unresectable or metastatic renal cell carcinoma. Invest New Drug. e-pub, 2011
6)Rini B, Szczylik C and Tannir NM:AMG 386 in combination with sorafenib in patients(pts)with metastatic renal cell cancer(mRCC):a randomized, double-blind, placebo-controlled, phase Ⅱ study. J Clin Oncol 29, 2011(suppl 7, abstr 309)
7)Hainsworth JD, Spigel DR and Burris HA 3rd:Phase Ⅱ trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma. J Clin Oncol 28:2131-2136, 2010
8)Escudier B:Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma:a randomised, double-blind phase Ⅲ trial. Lancet 370:2103-2111, 2007
9)Escudier B, Bellmant J, Négrier S, et al:Phase Ⅲ trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma(AVOREN):final analysis of overall survival. J Clin Oncol 28:2144-2150, 2010
10)Motzer RJ:Stage migration and increasing proportion of favorable-prognosis metastatic renal cell carcinoma patients. Cancer 116:347-354, 2010
11)Rini B:Axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma(mRCC):results of phase Ⅲ AXIS trial. ASCO annual meeting 2011, abstract 4503
掲載誌情報